Share

FDA Clears Dexcom G7

Dexcom announced recently that the FDA has cleared its next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all types of diabetes ages two years and older. Dexcom says it is working closely with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems as quickly as...
Share

New Endocrine Society Clinical Practice Guideline Examines Better Ways to Manage Hypoglycemia in People with Diabetes

People with diabetes are benefiting from advances in medications and technologies to lower their risk of hypoglycemia, according to a Clinical Practice Guideline issued today by the Endocrine Society. The guideline, titled “Management of Individuals with Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline,” was published online and will appear in the March 2023 print...
Share

Study Links Diabetes and Worse Outcomes in Long-Term Survivors of Metastatic Breast Cancer

Women who are longer-term survivors of metastatic breast cancer may have a worse survival rate if they have diabetes and poorly controlled blood sugar levels, according to a study presented at ENDO 2022. The authors of the study point out that a well-established relationship between diabetes and breast cancer exists, but it’s still unclear how...
Share

Control Issues: The Latest Endocrine Society Guideline Tackles Hyperglycemia in Hospitalized Patients

With new technology and new drugs changing diabetes treatment at an unprecedented pace, the Endocrine Society’s “Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Guideline” looks through the latest evidence on glycemic control for the most comprehensive guidance on selecting the optimal approach in hospitalized patients. The practice of...
Share

New Report Highlights Reveal Future of Insulin Biosimilars

Last summer, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. The FDA granted approval for insulin glargine-yfgn to Mylan Pharmaceuticals Inc., who is marketing the product as Semglee. Semglee...